DataVXACS NanoPaper
journal article·2020-06-23Open access

Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic

Carsten Weiss, Marie Carriere, Laura Fusco, Ilaria Capua, Jose Angel Regla-Nava, Matteo Pasquali, James A. Scott, Flavia Vitale, Mehmet Altay Unal, Cecilia Mattevi, Davide Bedognetti, Arben Merkoçi, Ennio Tasciotti, Açelya Yilmazer, Yury Gogotsi, Francesco Stellacci, Lucia Gemma Delogu

ACS Nano· Volume 14· Issue 6
Publisher pageOpen full text
Source abstract

Abstract

The COVID-19 outbreak has fueled a global demand for effective diagnosis and treatment as well as mitigation of the spread of infection, all through large-scale approaches such as specific alternative antiviral methods and classical disinfection protocols. Based on an abundance of engineered materials identifiable by their useful physicochemical properties through versatile chemical functionalization, nanotechnology offers a number of approaches to cope with this emergency. Here, through a multidisciplinary Perspective encompassing diverse fields such as virology, biology, medicine, engineering, chemistry, materials science, and computational science, we outline how nanotechnology-based strategies can support the fight against COVID-19, as well as infectious diseases in general, including future pandemics. Considering what we know so far about the life cycle of the virus, we envision key steps where nanotechnology could counter the disease. First, nanoparticles (NPs) can offer alternative methods to classical disinfection protocols used in healthcare settings, thanks to their intrinsic antipathogenic properties and/or their ability to inactivate viruses, bacteria, fungi, or yeasts either photothermally or via photocatalysis-induced reactive oxygen species (ROS) generation. Nanotechnology tools to inactivate SARS-CoV-2 in patients could also be explored. In this case, nanomaterials could be used to deliver drugs to the pulmonary system to inhibit interaction between angiotensin-converting enzyme 2 (ACE2) receptors and viral S protein. Moreover, the concept of "nanoimmunity by design" can help us to design materials for immune modulation, either stimulating or suppressing the immune response, which would find applications in the context of vaccine development for SARS-CoV-2 or in counteracting the cytokine storm, respectively. In addition to disease prevention and therapeutic potential, nanotechnology has important roles in diagnostics, with potential to support the development of simple, fast, and cost-effective nanotechnology-based assays to monitor the presence of SARS-CoV-2 and related biomarkers. In summary, nanotechnology is critical in counteracting COVID-19 and will be vital when preparing for future pandemics.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

NanomaterialsCatalysis & surfaces

OpenAlex topics: SARS-CoV-2 detection and testing · Nanoplatforms for cancer theranostics · SARS-CoV-2 and COVID-19 Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Biological and Chemical Systems, Biological Information Processing, Karlsruhe Institute of Technology, Campus North, Hermann-von-Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany

Univ. Grenoble Alpes, CEA, CNRS, IRIG, SyMMES-CIBEST, F-38000 Grenoble, France

Department of Chemical and Pharmaceutical Sciences, University of Trieste, 34127 Trieste, Italy

Cancer Research Department, Sidra Medicine, Doha, Qatar

One Health Center of Excellence, University of Florida, Gainesville, Florida 32611, United States

Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, United States

Department of Chemical & Biomolecular Engineering, Rice University, Houston, Texas 77251, United States

Department of Chemistry, Rice University, Houston, Texas 77251, United States

Department of Materials Science and Nanoengineering, Rice University, Houston, Texas 77251, United States

Dalla Lana School of Public Health, University of Toronto, 223 College Street, M5T 1R4 Toronto, Ontario, Canada

Department of Neurology, Bioengineering, Physical Medicine & Rehabilitation, Center for Neuroengineering and Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States

Center for Neurotrauma, Neurodegeneration, and Restoration, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania 19104, United States

Stem Cell Institute, Ankara University, Ankara, 06100 Turkey

Department of Materials, Imperial College London, London SW7 2AZ, United Kingdom

Nanobioelectronics & Biosensors Group, Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST, Campus UAB, 08193 Bellaterra, Spain

ICREA - Institució Catalana de Recerca i Estudis Avançats, ES-08010 Barcelona, Spain

Orthopedics and Sports Medicine, Houston Methodist Hospital, Houston, Texas 77030, United States

Department of Plastic Surgery, MD Anderson, Houston, Texas 77230, United States

Department of Biomedical Engineering, Faculty of Engineering, Ankara University, Ankara, 06100 Turkey

A.J. Drexel Nanomaterials Institute, and Materials Science and Engineering Department, Drexel University, Philadelphia, Pennsylvania 19104, United States

Institute of Materials, Ecole Polytechnique Federale de Lausanne (EPFL), 1015 Lausanne, Switzerland

Interfaculty Bioengineering Institute, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland

Department of Biomedical Sciences, University of Padua, 35122 Padova, Italy

References (100+)

Show source-provided references
1. 10.1134/S000629791607006310.1134/S0006297916070063 ↗
2. 10.1089/hum.1990.1.3-33110.1089/hum.1990.1.3-331 ↗
3. 10.2165/00003495-200060020-0000210.2165/00003495-200060020-00002 ↗
4. 10.1038/s41565-020-0687-410.1038/s41565-020-0687-4 ↗
5. 10.1038/nrg376310.1038/nrg3763 ↗
6. 10.1038/gt.2016.7910.1038/gt.2016.79 ↗
7. 10.1016/S0140-6736(12)61728-010.1016/S0140-6736(12)61728-0 ↗
8. 10.1007/s40138-018-0162-910.1007/s40138-018-0162-9 ↗
9. The Top 10 Causes of Death. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death (accessed 2020-05-03).
10. 10.1038/s41564-020-0695-z10.1038/s41564-020-0695-z ↗
11. WHO report-98, Johns Hopkins University. www.coronavirus.jhu.edu/map.html (accessed 2020-05-19).
12. 10.1177/014556132092076210.1177/0145561320920762 ↗
13. 10.1016/S0140-6736(20)30183-510.1016/S0140-6736(20)30183-5 ↗
14. 10.7326/M20-050410.7326/M20-0504 ↗
15. 10.1016/j.dsx.2020.03.01310.1016/j.dsx.2020.03.013 ↗
16. 10.1016/j.dsx.2020.03.01310.1016/j.dsx.2020.03.013 ↗
17. 10.1172/JCI13887110.1172/JCI138871 ↗
18. 10.1080/09273948.2020.173850110.1080/09273948.2020.1738501 ↗
19. 10.1016/j.bbi.2020.03.03110.1016/j.bbi.2020.03.031 ↗
20. 10.1038/s41586-020-2012-710.1038/s41586-020-2012-7 ↗
21. 10.1016/j.jare.2020.03.00510.1016/j.jare.2020.03.005 ↗
22. 10.1016/j.cell.2020.04.00410.1016/j.cell.2020.04.004 ↗
23. 10.1007/s00134-020-05985-910.1007/s00134-020-05985-9 ↗
24. 10.1016/j.cell.2020.02.05210.1016/j.cell.2020.02.052 ↗
25. 10.1016/j.cell.2020.03.04510.1016/j.cell.2020.03.045 ↗
26. 10.1016/j.immuni.2020.04.00310.1016/j.immuni.2020.04.003 ↗
27. 10.1038/s41586-020-2286-910.1038/s41586-020-2286-9 ↗
28. 10.1016/j.immuni.2020.03.00710.1016/j.immuni.2020.03.007 ↗
29. 10.1007/s40475-020-00201-610.1007/s40475-020-00201-6 ↗
30. 10.1038/s41421-020-0153-310.1038/s41421-020-0153-3 ↗
31. 10.1001/jama.2020.601910.1001/jama.2020.6019 ↗
32. 10.1016/j.apsb.2020.02.00810.1016/j.apsb.2020.02.008 ↗
33. 10.1016/j.nano.2016.08.01610.1016/j.nano.2016.08.016 ↗
34. 10.1177/204993611771359310.1177/2049936117713593 ↗
35. 10.1002/smll.20150085410.1002/smll.201500854 ↗
36. 10.1021/acs.molpharmaceut.5b0033510.1021/acs.molpharmaceut.5b00335 ↗
37. 10.15252/embj.2010511410.15252/embj.20105114 ↗
38. 10.1016/j.cell.2020.04.03510.1016/j.cell.2020.04.035 ↗
39. 10.1016/j.jconrel.2015.10.01210.1016/j.jconrel.2015.10.012 ↗
40. 10.1002/wnan.153010.1002/wnan.1530 ↗
41. 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-310.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3 ↗
42. 10.1002/anie.20120111410.1002/anie.201201114 ↗
43. 10.1093/clinids/2.1.4010.1093/clinids/2.1.40 ↗
44. 10.1101/cshperspect.a00495210.1101/cshperspect.a004952 ↗
45. 10.1038/nrmicro334610.1038/nrmicro3346 ↗
46. 10.1002/cbic.20100077610.1002/cbic.201000776 ↗
47. 10.1021/jacs.5b1295010.1021/jacs.5b12950 ↗
48. 10.1016/j.pharmthera.2009.05.00110.1016/j.pharmthera.2009.05.001 ↗
49. 10.1021/acsmacrolett.5b0091710.1021/acsmacrolett.5b00917 ↗
50. 10.1021/acsnano.8b0161610.1021/acsnano.8b01616 ↗
51. 10.1021/bc900215b10.1021/bc900215b ↗
52. 10.1016/j.bmc.2018.02.01210.1016/j.bmc.2018.02.012 ↗
53. 10.1126/science.aar622110.1126/science.aar6221 ↗
54. 10.1038/nmat505310.1038/nmat5053 ↗
55. 10.1126/sciadv.aax931810.1126/sciadv.aax9318 ↗
56. 10.1021/acsnano.9b0813310.1021/acsnano.9b08133 ↗
57. 10.3389/fbioe.2019.0029510.3389/fbioe.2019.00295 ↗
58. 10.7150/thno.4006810.7150/thno.40068 ↗
59. 10.1016/j.ijpharm.2018.12.06810.1016/j.ijpharm.2018.12.068 ↗
60. NIH Clinical Trial of Investigational Vaccine for COVID-19 Begins. https://www.niaid.nih.gov/news-events/nih-clinical-trial-investigational-vaccine-covid-19-begins (accessed 2020-05-05).
61. Draft Landscape of COVID-19 Candidate Vaccines. https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines (accessed 2020-05-22).
62. 10.1038/nmat278410.1038/nmat2784 ↗
63. 10.1371/journal.pone.002668410.1371/journal.pone.0026684 ↗
64. 10.1038/522026a10.1038/522026a ↗
65. 10.1038/nature1830010.1038/nature18300 ↗
66. Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19). https://clinicaltrials.gov/ct2/show/NCT04283461?term=NCT04283461&draw=2&rank=1 (accessed 2020-05-05).
67. Moderna’s Work on a Potential Vaccine Against COVID-19. www.modernatx.com/modernas-work-potential-vaccine-against-covid-19 (accessed 2020-05-03).
68. 10.1038/s41467-020-16505-010.1038/s41467-020-16505-0 ↗
69. A Study of a Candidate COVID-19 Vaccine (COV001). https://clinicaltrials.gov/ct2/show/NCT04324606?term=NCT04324606&draw=2&rank=1 (accessed 2020-05-05).
70. van Doremalen N. · bioRxiv · 2020
71. Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus. https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine (accessed 2020-05-22).
72. 10.1126/science.abc193210.1126/science.abc1932 ↗
73. 10.1371/journal.ppat.100521510.1371/journal.ppat.1005215 ↗
74. 10.1128/JVI.03566-1410.1128/JVI.03566-14 ↗
75. 10.1038/s41541-018-0089-x10.1038/s41541-018-0089-x ↗
76. 10.1016/j.coi.2017.06.00510.1016/j.coi.2017.06.005 ↗
77. 10.1016/j.smim.2018.05.00110.1016/j.smim.2018.05.001 ↗
78. Vaccines with MF59 Adjuvant Expand the Antibody Repertoire To Target Protective Sites of Pandemic Avian H5N1 Influenza Virus. https://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=32160 (accessed 2020-05-22).
79. 10.1002/jps.2331110.1002/jps.23311 ↗
80. 10.1080/14760584.2016.121363210.1080/14760584.2016.1213632 ↗
81. 10.2165/11591760-000000000-0000010.2165/11591760-000000000-00000 ↗
82. 10.1088/2515-7639/ab931710.1088/2515-7639/ab9317 ↗
83. 10.1038/s41467-017-01015-310.1038/s41467-017-01015-3 ↗
84. 10.1016/j.carbon.2020.01.00310.1016/j.carbon.2020.01.003 ↗
85. 10.1016/j.biomaterials.2013.02.05210.1016/j.biomaterials.2013.02.052 ↗
86. 10.1016/j.biomaterials.2016.01.06410.1016/j.biomaterials.2016.01.064 ↗
87. 10.1186/1479-5876-12-13810.1186/1479-5876-12-138 ↗
88. 10.3389/fimmu.2017.0094310.3389/fimmu.2017.00943 ↗
89. 10.12932/ap-200220-077210.12932/ap-200220-0772 ↗
90. Novavax To Receive up to $388 Million Funding from CEPI for COVID-19 Vaccine Development and Manufacturing. http://ir.novavax.com/news-releases/news-release-details/novavax-receive-388-million-funding-cepi-covid-19-vaccine (accessed 2020-05-22).
91. 10.1038/srep1957010.1038/srep19570 ↗
92. 10.4161/hv.2958910.4161/hv.29589 ↗
93. 10.1039/C6TB01131D10.1039/C6TB01131D ↗
94. 10.1021/acsnano.5b0475110.1021/acsnano.5b04751 ↗
95. 10.1021/acsnano.8b0475810.1021/acsnano.8b04758 ↗
96. 10.1016/j.nano.2019.03.00410.1016/j.nano.2019.03.004 ↗
97. 10.3390/pharmaceutics1202017110.3390/pharmaceutics12020171 ↗
98. 10.1016/S0140-6736(20)30628-010.1016/S0140-6736(20)30628-0 ↗
99. 10.1101/2020.03.02.2002997510.1101/2020.03.02.20029975 ↗
100. 10.1080/17425247.2018.142005310.1080/17425247.2018.1420053 ↗